Evidence map›Paper›PMID 41646014›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Xanthatin Targets CISD1 to Drive Ferroptosis and Mitophagy as a Dual Anticancer Strategy in Triple-Negative Breast Cancer.

Qinwen Liu, Haojie Chen, Xiang Li, Jingxin Liu, Yiwen Li, Zhenyi Shi, Shenshen Guo, Qingfeng Du, Aiping Lu, Daogang Guan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qinwen LiuNeurosurgery Center, Department of Cerebrovascular Surgery, Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China.
Haojie ChenDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.
Xiang LiDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.
Jingxin LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.
Yiwen LiDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.
Zhenyi ShiDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.
Shenshen GuoDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.
Qingfeng DuGuangdong Basic Research Center of Excellence for Integrated Traditional and Western Medicine For Qingzhi Diseases, Guangzhou, P. R. China.
Aiping LuInstitute of Systems Medicine and Health Sciences, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, P. R. China.
Daogang GuanDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P. R. China.ORCID https://orcid.org/0000-0003-1414-0189

Funding

China Postdoctoral Science Foundation 2025M78355Guangdong Provincial Science and Technology Innovation Strategy Special Fund 2020B1212030006International Science and Technology Corporation Key Program of Jiangxi Province 20232BBH80012National Natural Science Foundation of China 32070676National Natural Science Foundation of China 32370683National Natural Science Foundation of China 82503400National Postdoctoral Researchers Program GZC20251414Natural Science Foundation of Guangdong Province 2021A1515010737 2023A1515012902Theme-based Research Scheme of Research Grants Council of Hong Kong SAR T12-201/20-R
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Here, we identify xanthatin, a sesquiterpene lactone from Xanthium species, as a potent inhibitor of TNBC cell growth with minimal toxicity to normal cells. Transcriptomic analyses revealed that xanthatin activates ferroptosis, evidenced by elevated ROS, lipid peroxidation, and Fe

Indexed as

FerroptosisFuransMitophagyTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMitochondrial ProteinsCISD1 protein, humanFuransMitochondrial ProteinsxanthatinCISD1ferroptosismitochondrial autophagytriple‐negative breast cancerXanthatin

Identifiers

PMID41646014
PMCPMC13073315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.